Explore approved biosimilar medicines
| # | Medicine | Status | Active Substance | Therapeutic Area | Developer | Published Date |
|---|---|---|---|---|---|---|
| 91 | Ponlimsi | Authorised | denosumab | Bone Resorption;Osteoporosis;Osteoporosis, Postmenopausal | Teva GmbH | 19-09-2025 |
| 92 | Nyvepria | Authorised | pegfilgrastim | Pfizer Europe MA EEIG | 23-11-2020 | |
| 93 | Degevma | Authorised | denosumab | Giant Cell Tumor of Bone;Neoplasms, Bone Tissue | Teva GmbH | 19-09-2025 |
| 94 | Opuviz | Authorised | aflibercept | Wet Macular Degeneration;Macular Edema;Diabetes Complications;Retinal Vein Occlusion | Samsung Bioepis NL B.V. | 20-09-2024 |
| 95 | Bekemv | Authorised | Eculizumab | Hemoglobinuria, Paroxysmal | Amgen Technology (Ireland) UC | 21-02-2023 |
| 96 | Zvogra | Authorised | denosumab | Giant Cell Tumor of Bone;Neoplasms, Bone Tissue | Stada Arzneimittel AG | 19-09-2025 |
| 97 | Stoboclo | Authorised | denosumab | Osteoporosis, Postmenopausal;Osteoporosis;Bone Resorption | Celltrion Healthcare Hungary Kft. | 13-12-2024 |
| 98 | Usymro | Authorised | ustekinumab | Crohn Disease;Psoriasis;Arthritis, Psoriatic | Gedeon Richter Plc. | 20-06-2025 |
| 99 | Bilprevda | Authorised | denosumab | Giant Cell Tumor of Bone;Neoplasms, Bone Tissue | Sciencepharma Sp. z o.o | 25-07-2025 |
| 100 | Rimmyrah | Authorised | ranibizumab | Wet Macular Degeneration;Macular Edema;Diabetes Complications;Myopia, Degenerative;Choroidal Neovascularization | Qilu Pharma Spain S.L. | 10-11-2023 |
Ready to transform your strategic intelligence? Let's talk
Get latest pharmaceutical insights, blogs, and strategic updates directly in your inbox.